Enanta Pharma Commences Dosing In Phase 1 COVID-19 Trial

Enanta Pharmaceuticals Inc ENTA has dosed the first subject in its Phase 1 trial of EDP-235, a coronavirus 3CL protease inhibitor, specifically designed as a once-daily, oral treatment for COVID-19.

  • The Company plans to report data from this study in Q2 of 2022, and, assuming positive findings, Enanta expects to advance EDP-235 to the next stage of clinical development in 2H of 2022.
  • This first-in-human Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics of oral EDP-235 compared to placebo in healthy volunteers. 
  • All SAD and MAD cohorts will enroll eight participants randomized to receive EDP-235 or placebo in a 3:1 ratio.
  • Related: Enanta Plans To Start Human Trials For Its COVID-19 Candidate In 2022.
  • Preclinical data show that EDP-235 potently blocks the replication of SARS-CoV-2 in multiple cellular models. 
  • Preclinical studies demonstrate that EDP-235 has good oral bioavailability without ritonavir boosting and favorable distribution into lung cells and other key target tissues.
  • Also See: Safety Signals Force Enanta To Stop EDP-721 HBV Program.
  • Price Action: ENTA shares are down 2.99% at $60.35 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareSmall CapMoversTrading IdeasGeneralBriefsCOVID-19 CoronavirusPhase 1 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!